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Abstract
Background: In 2004 Niger established a large scale schistosomiasis and soil-transmitted helminths control programme
targeting children aged 5–14 years and adults. In two years 4.3 million treatments were delivered in 40 districts using school
based and community distribution.
Method and Findings: Four districts were surveyed in 2006 to estimate the economic cost per district, per treatment
and per schistosomiasis infection averted. The study compares the costs of treatment at start up and in a subsequent
year, identifies the allocation of costs by activity, input and organisation, and assesses the cost of treatment. The cost
of delivery provided by teachers is compared to cost of delivery by community distributers (CDD). The total economic
cost of the programme including programmatic, national and local government costs and international support in four
study districts, over two years, was US$ 456,718; an economic cost/treatment of $0.58. The full economic delivery cost
of school based treatment in 2005/06 was $0.76, and for community distribution was $0.46. Including only the
programme costs the figures are $0.47 and $0.41 respectively. Differences at sub-district are more marked. This is
partly explained by the fact that a CDD treats 5.8 people for every one treated in school. The range in cost
effectiveness for both direct and direct and indirect treatments is quantified and the need to develop and refine such
estimates is emphasised.
Conclusions: The relative cost effectiveness of school and community delivery differs by country according to the
composition of the population treated, the numbers targeted and treated at school and in the community, the cost and
frequency of training teachers and CDDs. Options analysis of technical and implementation alternatives including a financial
analysis should form part of the programme design process.
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Introduction
Schistosomiasis is one of the most prevalent chronic infectious
diseases found world-wide and is associated with anaemia, chronic
pain, diarrhoea, and under nutrition. It is recognised as a major
public health problem in many rural areas, particularly in school-
age children. With affordable and sustained control measures
morbidity and transmission can be decreased.
Robust studies on the implementation of large scale control of
schistosomiasis and soil transmitted helminths (STH) are required
to strengthen the evidence base on the cost-effectiveness and
affordability of such investment [1–3]. In particular, evidence on
effectiveness is needed to support the strategic planning for
expanded treatment and global coverage as well as for national
vertical and integrated Neglected Tropical Disease (NTD)
programmes. The objectives of this study are to identify: the cost
of the Mass Drug Administration (MDA) programme; the cost per
person treated; and the costs of treatment as delivered by school
based staff and community distributers.
A number of studies have identified the costs of targeted and
MDA for schistosomiasis control [4–9]. These have, with the
exception of [4,9], provided empirical evidence of school based
approaches. This paper provides the cost of MDA treatment and
compares the costs of the school and community based
distribution systems used. It assesses the evidence from other
MDA programmes taking account of factors such as the level of
school enrolment, coverage levels to consider the general
guidelines that can be taken from these works.
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Administration in Niger
In 2004 Niger established a national programme to control
schistosomiasis and soil-transmitted helminths (PNLBG) supported
by the Schistosomiasis Control Initiative (SCI), funded by the Bill
and Melinda Gates foundation [10]. Its objective in line with
Resolution WHA54.19 was to treat 75% of school age children at
risk of infection and in communities where prevalence is over 50%
to also treat at risk adults. The purpose being to reduce the
morbidity related to schistosomiasis infection to a level at which it
would not constitute a public health problem [11].
The primary school net enrolment rate (NER) in 2004 in Niger
was 41% (UNESCO UIS global education database Table 5,
Enrolment ratios by International Standard Classification of
Education (ISCED) level), lower in rural areas; and considerably
less than the rate of 68% for Sub Saharan Africa (SSA). To achieve
high treatment coverage in targeted school age children and at risk
adults two treatment strategies, school-based and community-based
distribution, were established. Treatment for S. haematobium was
provided every two years in most endemic areas, and annually in
high prevalence areas to reduce initial levels. School-based
distribution was provided by trained teachers who distributed the
drugs to students in the schools. Children not attending school could
receive treatment either inthe schools or from the Community Drug
Distributor (CDD) at home or at another fixed treatment location.
The MDA programme was established and rolled out over 2
years from April 2004 across 40 districts in all 7 regions of the
country, including the capital city Niamey. The programme
activities were implemented progressively commencing in the
Tilaberi and Dosso regions. In 2004/05, 1,627,828 treatments
were delivered in 22 districts and in 2005/06 2,683,121 treatments
were delivered in 40 districts. Figure 1 outlines the main MDA
programme activities.
Initial meetings and agreement of the programme with the
regional and district administrations were followed by a prevalence
survey and mapping to prioritise areas for MDA. A national
workshop and practical field sessions to develop capacity in the
diagnosis of schistosomiasis was organised. Further capacity-
building workshops and training for staff in organisation,
management and implementation of MDA was provided to key
district health and educational inspectorate staff in an initial
national workshop. These staff then trained clinic staff, health
workers and head teachers though district meetings. Training was
provided on the calculation of drug requirements, drug distribu-
tion organisation, the management of side effects and the
reporting of results. Community and school-based drug distribu-
tors were trained in the use of dose poles (to determine drug
dosage), and the completion of treatment forms.
The national programme developed, piloted, printed and
delivered information, education and communication (IEC)
materials for distribution to the districts. These materials included
posters and a booklet for use in schools and communities as well as
technical sheets for those administering the drugs. Drugs were
procured centrally by SCI on behalf of countries which SCI
supported in West and East Africa [12]. The drugs were sent
directly from the National store to the districts. The districts and
inspectorates repacked the drugs and IEC material for distribution
to or collection by clinics and schools. Social mobilisation activities
were undertaken at various administrative levels. National radio
and television broadcasts were undertaken in three local languages
and in French, organised by the PNLBG; local radio broadcasts
were organised by the districts; village criers were organised by
clinics to inform communities about the logistics of the MDA.
A rally to launch the campaign was undertaken and organised
by an host region; it involved a day of speeches, dance and
hospitality supported by national, regional and programme
dignitaries and was broadcast on national radio and television.
Treatments were delivered at schools by teachers; CDDs
provided treatment by going from door to door and at other
fixed points supervised by clinic, district and regional staff.
Technical and management support and supervision were
provided to the districts by national staff.
At the end of the MDA unused drugs and monitoring reports
were collected by national staff. A one day post MDA evaluation
meeting was held in each participating region attended by
national, regional and district staff. A summary of the partner
roles and responsibilities is identified in Table 1.
Methods
A protocol for the cost and resource use study was agreed with
Niger Ministries of Health and Education at national and local
government level. Written informed consent to participate in the
programme longitudinal surveillance and monitoring research was
obtained from the children’s parents or guardians, or head
teachers according to the study protocol approved by St Mary
Research Ethics Committee of Imperial College, UK, 2003, (EC
No 03.36, R&D No: 03/SB/003E) and amended 2005 St Mary’s
(REC Ref: AM2003).
This was a retrospective study which covered a two year period
from April 2004 to May 2006, including the first and second years
of MDA and related programme activities in four health districts.
All data on first year costs at national, regional, district, and sub
district levels were taken from the PNLBG accounts and receipts
and records of staff missions or activities. Second year cost data for
national and regional level activities were taken from receipts.
District and sub district, school and community MDA resource use
data for 2005 were collected in June 2006 through a retrospective
survey. The four health districts: Kollo, Tera, Tilaberi, (Tilaberi
region) and Gaya (Dosso region) are all located in the Niger River
Valley, and were in the first phase of implementation. The control
programme had previously established sites for longitudinal
monitoring of prevalence and morbidity in these districts.
Author Summary
Schistosomiasis and soil-transmitted helminth control
programmes are important, relatively low cost means to
improve the health of those affected, in particular rural
school age children. It can also reduce schistosomiasis
related morbidity in their later lives. The paper presents
information on the implementation and costs of a large
scale national programme in Niger. The total economic
cost per treatment was $0.58. This includes programme,
government and international costs. Two systems, school
based and community delivery were used to treat children
and targeted adults. Contrary to findings in some countries
we find that school based delivery is less cost effective
than community delivery. This is due to the low proportion
of the population targeted and treated by the school
based system. Treating adults as well as children increased
the numbers treated and reduced the overall cost per
treatment. Prevalence and infection is higher in children
than adults and overall effectiveness in terms of infection
averted is affected. The cost per infection averted is
assessed for direct treatment and direct and indirect
treatment effects. The study expands the evidence
available for decision makers involved in programme
planning and design, funding and implementation.
Cost Effectiveness of Schistosomiais Control
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and resources used by district and sub district health staff, and by
the education inspectorate and school staff in the 2005 MDA
delivery. Questionnaires were designed and tested, and a 2 day
training workshop was undertaken in 2006 to familiarise and train
the schistosomiasis MDA district co-ordinators, responsible for the
data collection.
The questionnaires covered the usage of: vehicles, fuel and
other equipment and materials used in the MDA and in training,
time spent in different activities by staff at regional, district, and
clinic level, payments made to CDDs, and for local services.
Survey data on 2005 MDA delivery costs were verified with
PNLBG receipts. Drug usage was obtained from district and from
PNLBG records. Coverage figures were obtained from district
treatment registers and the national annual treatment summary.
Longitudinal surveillance and monitoring data were obtained
from records of the Centre de Recherche Medicale ´ et Sanitaire
(CERMES) and from the PNLBG register of activities and
receipts.
Determination of the economic cost of treatment
The study examines the economic costs of the MDA
programme in its first and second years. The economic costs
include the full value of the resources used. Where this is not
adequately represented by the financial or market cost, an
opportunity cost is used (see Table S4). The main cost elements
include: the programme specific expenditure; the opportunity cost
or value of government contributions related to in-kind costs of
using local government staff and vehicles and the value of CDD’s
time (taken as the daily agricultural labour rate); and the
international costs of programme co-ordination, reporting and
technical support.
Programme costs include directly incurred capital costs;
recurrent costs; and variable costs. Capital costs incurred by the
programme included central level purchase of Information
Technology (IT), medical and laboratory equipment and other
electrical and mechanical goods and furniture used to equip the
PNLBG office including the purchase of four 464 vehicles for
PNLBG (Table S1). Capital costs were annualised over their useful
Figure 1. The main steps in the MDA programme. Figure 1 presents the component activities of the MDA process. Activities mainly occurring in
the first year are shown as well as annual activities.
doi:10.1371/journal.pntd.0001326.g001
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annual cost of owning and operating an asset over its lifespan.
Programme recurrent costs including staff costs, office and
vehicle running costs, and programme variable costs were
collected from the programme records, accounts and receipts.
These costs were apportioned in relation to the time spent by
programme staff on MDA activities and the proportion of that
time allocated to study areas.
Variable costs related to perdiems, materials and services
incurred in relation to the programme activities. Centralised
activities (e.g. organisation and provision of national training for
all district technicians, planning and organisation) and regional
activities (e.g. MDA launch) were equally apportioned in relation
to the number of districts in the MDA and share of the four study
districts. Location specific activity costs such as supervision,
mapping, central delivery of drugs to districts were allocated on
the basis of costs incurred in the study districts.
Sentinel monitoring informs the national treatment strategy.
The costs of sentinel site monitoring were apportioned to the study
districts on the basis of study area treatments relative to national
treatments.
Government staff costs were based on salary costs collected
through questionnaire and the Government salary grid. District
and sub district vehicle usage was calculated from questionnaire
returns and costed using hire rates. These values are estimated to
reflect the opportunity cost of using the resources for the MDA
rather than for an alternative activity.
Costs were collated and classified by three levels of organisation
(national, regional & district, or community), type of activity
(training, support & supervision, baseline & monitoring, reporting,
evaluation, advocacy, mobilisation & IEC) and cost type (fuel,
transport, materials, services, drugs, per diems, temporary
contracts and office related recurrent costs).
Prices are in constant 2005 terms (Table S4). Foreign exchange
was converted at the fixed rate of CFA 655/Euro and $1.244/
Euro (http://www.federalreserve.gov/release/January 2 2009).
Discounted economic analysis was undertaken using discount rate
of 3% in line with World Bank rates [13]. The cost of a treatment
includes both albendazole and praziquantel.
School based and community delivery system cost
calculation
Community and school based delivery was and is practised
nationally. The costs incurred by the two systems were equally
attributed at national, regional and district level. It is at sub district
level that the systems differ in the organisation and implementa-
tion of the delivery activities. The school and sub district delivery
services used a partial analysis which took account of these cost
components only.
The cost of delivery using a CDD and of using a teacher was
calculated. These costs included per diems and travel allowances
for CDD and head teacher training; allowances for delivery
(applicable only for CDD), health clinic staff costs for CDD
selection (per diems and fuel) and supervision (fuel only). The
training of one or more teachers and their supervision in schools
was undertaken by the school head, no financial cost was incurred.
Joint activity costs of the district health and education inspectorate
(training, drug repacking, drug delivery to sub districts and schools
and supervision) would be incurred despite the system. These have
not been included in the partial analysis but an allowance has been
estimated to allow comparability with other MDA programmes.
Cost effectiveness analysis
The effectiveness of treatment was calculated as the difference
between the population with schistosomiasis infection at baseline
and follow-up survey. The prevalence rates used are from a
longitudinal health impact study (Nadine Seward (2007) Niger
Three Years Data Analysis, SCI internal report (unpublished)).
To assess the effectiveness of the programme’s direct and direct
and indirect treatment effects an assessment of the impact in the
treated population and in the targeted population was made.
Treatment costs were calculated as the number of treatments in
Table 1. Roles and responsibilities in the Niger schistosomiasis and STH MDA.
National Region & Department Clinic, School, Community
N Advocacy meetings with national, regional and
district health and education administrations
Regional N Training by clinic nurse of community distributers
N Organisation of national prevalence survey N Disbursement of funds
to the districts, and
N The school head undertakes the training of
school staff for school based MDA.
N Training for diagnosis N Supervision of district MDA activities N Engagement of village criers to publicise community MDA
N Drug clearance and reception District N Organisation of MDA drug delivery to the
communities and MDA supervision of distributers
N Storage, repacking and delivery of drugs and
materials to districts
N Training of primary school heads
and clinic health staff;
N Supervision by Clinic Head Nurse of drug
delivery by CDD and in schools by headmasters
N Central training of trainers for regional and
district health and education staff
N Repacking and delivery of drugs and
materials to the clinics and to the sector
education authorities or schools
N Collation and reporting of treatments by clinic
nurse and by head teacher to inspectorate
N Support for national campaign inaugural rally N Supervision by district and inspectorate
of drug delivery in communities and schools.
N Response to secondary effects
reported to clinics initially
N Supervision, technical support of district MDA
organisation & delivery
N District level radio emission and diffusion N Disbursement of moneys for community MDA
N Collection of surplus drug supplies and
coverage forms
N Disbursement of moneys to the clinics
N Programme evaluation
N National radio and television diffusion
doi:10.1371/journal.pntd.0001326.t001
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2005/6.
Eight schools and four communities located in areas highly
endemic for schistosomiasis took part in a longitudinal health
impact study. The study used baseline and longitudinal follow-up
surveys one year post treatment to monitor: parasitological
indicators (prevalence and intensity of helminth disease examining
stool and urine samples following standard procedures using kato
katz and filtration methods [14]); morbidity indicators (anaemia
and associated pathology of schistosomiasis, assessed by ultrasound
examination following standard protocols developed by WHO)
and general indicators of height and weight. The baseline survey
enrolled 1659 children from 8 different schools in 3 regions prior
to the first MDA campaigns of 2004 and 2005. The number of
children enrolled from each school ranged from 179 to 299; with
almost equal numbers of children in age groups of 7, 8 & 11 years
old. Of those recruited 1193 (72%) were followed-up successfully
at year 1 and year 2 surveys. Adults and adolescents were
monitored in 4 sites in a single region. A total of 484 adolescents
and adults were recruited at baseline. Of these, 143 (30%) were
followed-up successfully at both year 1 and year 2 surveys. The
sample sizes was estimated using the same criteria as described in
[15].
The surveyed sites mirror the MDA treatment and represent
MDA performance in targeted populations taking into account the
treated and untreated participants in proportion to the MDA
coverage. Any indirect effect of reduced infection in untreated
pupils resulting from changes in the force of infection is reflected in
the intensity of infection [16] which is related to prevalence ([17]
provides more detail). To assess the wider impacts on the
community, untreated first year students were monitored in the
schools. Adults and adolescents were monitored at four sites.
Results
Total economic costs of treatment
The total economic cost of the programme including programme
specific expenditure, national and local government costs and
international technical support and programme co-ordination in
four study districts, over two years, was US$ 456,718 (Table 2); an
economic cost per treatment of $0.58. Excluding international costs,
the programme and government expenditure was $0.54 per
treatment. The programme expenditure per treatment was $0.44.
The average drugs cost was $0.28 per treatment. The numbers
treated in these two years totalled 818,562 (781,883, discounted at
3%).
The distribution of costs between the programme, the
government and international support are shown in Table 2.
Drugs accounted for 49% of the total economic cost (65% of
programme expenditure), variable costs accounted for 19% of the
economic cost (26% of programme expenditure). Overall there
was little difference in the total economic cost of the programme in
the four districts between the first and second years. However the
total economic cost per treatment in the first year was $0.68 and in
the second year was $0.51. Cost differences are shown in Table 3
and discussed below.
Excluding the MDA drug costs, the economic cost of the
programme in the four districts in the second year was 29% less
costly than the first year and treated 25% more people. Higher
costs in the first year of the programme are seen in programme
costs and international support. Three factors contribute to this.
The cost of the initial start up activities incurred in the first year
only. The activities involved advocacy, development of IEC
materials, prevalence surveys and data collection for planning
and the establishment of monitoring and evaluation (M&E)
activities, in particular the longitudinal monitoring sites (illustrat-
ed in figures 2 and 3), and repair and maintenance of the national
office. In the second year the programme was scaled up. This
reduced the apportioned share of recurrent and capital
Table 2. Discounted economic cost of the MDA programme for April 2004 to March 2006 in 4 districts (2005 prices).
Regional School, clinic International Cost
Cost Category National /District & community TC & drugs Total Distribution
Programme expenditure
Capital 10,226 10,226 2%
Recurrent 21,154 21,154 5%
Variable 35,532 17,667 35,261 88,460 19%
Drug cost 222,385 222,385 49%
Total Programme 66,912 17,667 35,261 222,385 342,226
Programme cost 66,912 17,667 35,261 222,385 342,226 75%
Government cost 3,585 10,721 67,559 81,865 18%
International tech. support 32,627 32,627 7%
Total Economic Cost 70,497 28,388 102,820 255,013 456,718 100%
doi:10.1371/journal.pntd.0001326.t002
Table 3. Annual economic cost of the MDA programme in
four districts (2005 prices).
Costs 2004/05 2005/06 % change
Programme cost 75,421 49,455 234%
Government cost 43,646 41,894 24%
International tech. support 24,082 9,810 259%
Drug cost 103,653 129,166 25%
Total costs 246,802 230,326 27%
Total costs excl. drugs 143,149 101,159 229%
Total costs discounted (3%) 239,614 217,104
Number treated 364,593 453,969 25%
Note costs are not discounted.
doi:10.1371/journal.pntd.0001326.t003
Cost Effectiveness of Schistosomiais Control
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area. In 2004/05 22 districts were treated and in 2005/06 40
districts were treated. Within the study area the population
treated in the second year which was 25% more than those
treated in the first year.
The distribution of variable expenditure (excluding drugs) by
activity in the study area is presented in Figures 2 and 3. These
show the relatively large proportion of expenditure on training and
on MDA delivery. It also highlights activities mainly undertaken at
establishment. Total programme variable costs in 2004/05 were $
Figure 2. 2004/05 Variable costs by activity in 4 districts (2005 prices). Total variable cost was $51,970 in the 4 districts. This includes start up
costs involving advocacy, the prevalence baseline, development of IEC materials and establishing monitoring sites. At sub district level, planning and
organisation is undertaken at the same time as training.
doi:10.1371/journal.pntd.0001326.g002
Figure 3. 2005/06 Variable costs by activity in 4 districts (2005 prices). Total variable cost was $40,318 in the 4 districts. At sub district level,
planning and organisation is undertaken at the same time as training. Compared with the previous year, 25% more people were treated.
doi:10.1371/journal.pntd.0001326.g003
Cost Effectiveness of Schistosomiais Control
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first year.
M&E costs include costs of process monitoring in 2004/5,
annual district and regional evaluations and programme health
impact monitoring undertaken through the National sentinel sites.
These costs amounted to an average of 13% of variable costs over
the 2 years. Table 4 presents the average allocation of cost by
category (capital, recurrent and variable) and type of input.
Labour related costs (salary plus per diems) and vehicle and fuel
costs account for 64% and 19% of all costs excluding drugs.
Sensitivity analysis was undertaken on major cost items. A 10%
increase in the cost of drugs would result in a 4.9% increase in the
total economic cost of treatment ($456,718), and a 6.5% increase
in the current programme cost ($342,226). A 10% increase in
perdiems and allowances would result in a 1.1% increase in the
total economic cost of treatment, or a 1.5% increase in the
programme cost, a 4.2% increase in the programme cost
excluding drug costs. A 10% increase in wages and salaries would
result in a 1.5% increase in the economic cost of treatment. It
would impact most on the government sector and distributer
opportunity costs increasing costs by 7.7%. The increase on the
programme cost would be 0.2% The sensitivity of total economic
cost to a saving in teacher training costs was explored. This
assumed community distributers would undertake the school
treatments for the same fixed allowance. Savings in teacher
training allowances are assumed, but not the economic cost of
their time which would still be required to support distributers in
school based treatment. Any savings in teacher time would be
offset by the increased opportunity cost of time for community
distributers. The impact of the net saving on the total economic
cost would be 2.9%. This is equivalent to a saving of 4.1% in the
programme cost. This provides an approximate scale of magnitude
within which to assess comparative costs of sub district delivery
systems below.
Cost of community based and school based delivery
systems
Sub district costs (i.e. clinic, school and community costs)
account for the largest portion of the economic cost by
administrative level. This is 23% of the total economic cost (based
on Table 2); so, it is important to understand the allocation and
usage.
Sub district variable programme costs include head teacher and
CDD per diems for training and CDD payments for distribution.
Sub district government costs include the opportunity cost for the
use of motorbikes (11%) and labour (89%). The opportunity cost
of labour is principally accounted for by the time of the teacher
and head teachers (61%), of the clinic staff in supervision (20%)
and CDD time for training and distribution (19%).
Table 5 presents the characteristics and costs of sub district
delivery. The economic cost per school based treatment and per
CDD treatment delivered was $0.36 (range $0.26–$0.55) and
$0.06 (range $0.04–$0.07) respectively. The programme cost per
school based treatment and per CDD treatment delivered was
$0.09 (range $0.07–$0.15) and $0.03 (range from $0.03–0.04)
respectively.
The full economic delivery cost of school based treatment in
2005/06 was $0.76, and community treatment was $0.46. If only
Table 4. Programme and government MDA costs (2004/06)
allocated by cost category.
Costs % distribution*
Capital Costs 5%
Recurrent Costs
Salary 38%
Vehicle & office fuel 10%
Office & other 2%
Communications 1%
Variable Costs
Perdiems 26%
Transport 4%
Fuel 5%
Material & services 9%
Total 100%
*Percentage based on discounted cost for the 2 years, $201,705 excluding
drugs and international costs.
doi:10.1371/journal.pntd.0001326.t004
Table 5. Characteristics and cost of community and school
based delivery in 4 districts 2005/06.
District GAYA KOLLO TERA TILLABERI
Characteristics
No. senior clinic
nurses (1 per clinic)
17 16 19 18
No. community drug
distributers (CDD)
206 156 300 291
No. schools in campaign 267 324 275 198
Teacher/CDD ratio 1.30 2.08 0.92 0.68
Population Targeted & Treated
Targeted village
population*
103,064 78,084 150,108 145,290
Targeted school related
population*
26,872 35,207 32,767 23,266
Treatments by CDDs 75,982 55,820 152,710 103,825
Treatments by teachers 25,121 19,715 12,406 17,245
Treatments
administered/CDD
369 358 509 357
Treatments
administered/teacher
94 61 45 87
Coverage in villages % 74% 71% 102% 71%
Coverage in schools % 93% 56% 38% 74%
Treated adults 46,653 37,402 69,801 58,895
Treated children 54,450 38,133 95,315 53,320
Overall coverage 78% 67% 90% 72%
Sub District Financial Costs of Treatment
Teacher cost/treatment $ 0.07 0.11 0.15 0.08
CD cost/treatment $ 0.04 0.04 0.03 0.04
Sub District Economic Costs of Treatment
Teacher cost/treatment $ 0.26 0.41 0.55 0.28
CD cost/treatment $ 0.07 0.07 0.05 0.06
*Targeted populations at school and in the village include both adults and
children.
Source: 2005 Survey data, unpublished programme planning data & treatment
data 2005/6 campaign.
doi:10.1371/journal.pntd.0001326.t005
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respectively.
The difference in costs is in part explained by the fact that a
CDD delivers 5.8 treatments for every one delivered in school. On
average each CDD delivered 407 treatments while each school
delivered 70.
Cost effectiveness of treatment
Over the 2 treatment cycles 530,300 treatments were provided
to an estimated 317,549 adults and 288,262 treatments were
provided to 241,218 children in the study areas in the regions of
Dosso and Tilaberi. Coverage in the target population in Gaya,
Dosso was 78% in both years, and was 69% and 71% in the three
districts monitored in Tilaberi.
Two estimates of the cost of treatment per case of infection
averted (Table 6) are presented. One includes only the direct
impacts of treatment and the other includes the direct and indirect
impacts of treatment. They provide minimum and maximum
limits of the true value. This is discussed further in the next section.
Including only the direct impacts on the treated population the
average cost per infection averted in treated children in the 4
districts over the two years was $1.10. Of the 317,549 adults
treated in a single round the cost per infection averted was $4.4
and over two rounds it is estimated to be $6.5. The overall cost per
infection averted in the treated population of children and adults is
calculated as $2.5.
If indirect treatment effects are included the average cost per
infection averted in targeted (treated and untreated) children in the
4 districts over the two years was $0.78. Of the 446,180 adults
targeted in a single round the cost per infection averted was $3.08
and over two rounds it is estimated to be $4.6. The overall cost per
infection averted in the targeted population of children and adults
is calculated as $1.78.
The higher cost of infection averted in adults reflects the lower
base prevalence rate. The longitudinal adult cohort followed up
over the 2 year period suffered high drop-out rates and its
composition was significant different at the 0.05 significance level.
Males in particular those who were infected with S. haematobium
infection were more difficult to retain at follow-up. The resulting
cohort of 116 adults had a lower proportion of males, and had a
lower base rate of infection (24.1%, (95% CI:16.35–31.93)) as
compared with the original baseline sample (39.62%
(95%CI:35.23–44.01)). To avoid this issue the results for the
sample monitored at the first year follow up are used and it is
conservatively assumed that the prevalence in the second follow up
did not change.
Discussion
The cost per treatment and prevalence figures relate to the
study sample of four districts located in the Niger River Valley.
This was and is an area of high disease prevalence and high
population density relative to other parts of the country. The costs
per person treated may be higher in lower density and more
remote areas. Likewise the cost per infection averted will be
greater in sub populations with lower changes in prevalence.
The cost study relied on the survey work for details of district
and sub district resource use. As the survey was undertaken almost
a year after the MDA, it may have been affected by recall bias. A
further limitation of the study is the delay in final analysis. This
limited follow-up work; the recent MDA’s confuse recall and some
key people have changed positions and locations. However, the
issues raised by the study analysis are still relevant and worthy of
further investigation.
One of the strengths of the study is the availability and use of
MDA health impact monitoring results to assess programme
effectiveness. Cost effectiveness studies are often obliged to use
trials data concerned with the efficacy of treatment [3] rather than
programme effectiveness as monitored in Niger. This potentially
allows us to capture direct and indirect treatment effects as
identified by Miguel and Kremer [18] and French et al [16]. Both
identify direct and indirect effects of treatment in terms of the
reduced transmission of Schistosoma mansoni in children in the
community including children not treated. The direct and indirect
impact quantified here represents a best case or maximum impact.
Further work based on intensity and force of infection based on the
work of French et al [16] is required to refine and triangulate the
estimate. Estimating only the direct effects of treatment in the
treated population provides a conservative estimate of infection
averted. Due to the definition of prevalence used in the study and
the data available, the prevalence estimate in the treated
population is under estimated (and consequently cost per
treatment is overestimated). The true value of the infections
averted is believed to be between these two estimates. There is a
40–42% difference in the cost per infection averted between the
‘‘best’’ and worst case scenarios. However the magnitude of
Table 6. Cost per infection of schistosomiasis averted for children and adults in four districts of Niger.
Region/Age
No.
Treatments
No.
People
Treated
No.
Targeted
Base
Prevalence*
Follow up
Prevalence*
Infection
Averted
(Targeted)
Infection
Averted
(Treated)
Treatment
cost $**
$/Infection
Averted
(Treated)
$/Infection
Averted in
(Targeted)
%
Difference
Tilaberi
–children
227,268 186,768 270,678 93.33% 33.57% 111,613 161,757 122,792 1.10 0.76 45%
Dosso –children 60,994 54,450 69,808 72.37% 19.30% 28,897 37,047 32,219 1.11 0.87 28%
Study area:
All children
288,262 241,218 340,486 140,509 198,804 155,011 1.10 0.78 42%
Adults 2004‘ 317,549 317,549 446,180 34.12% 18.43% 49,823 70,006 215,933 4.33 3.08 41%
Adults 2004
& 2005‘
530,300 317,549 446,180 34.12% 18.43% 49,823 70,006 324,436 6.51 4.63 41%
*Prevalence rates, SCI internal reports (unpublished). Base and follow up figures are significantly different at 95%CI (Table S3).
**Based on full economic costs of $0.68 (2004) and $0.51 (2005)/treatment.
‘Prevalence relates to baseline and follow up sample for year 1 in Tahoua region, no adults were monitored in the study area. Drop-out rate at follow up year 2 were
high and sample composition differed from baseline.
doi:10.1371/journal.pntd.0001326.t006
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developing more robust estimates.
The most effective means of delivering helminth treatment to
school age children has been debated in various papers. The
Partnership for Child Development (PCD) [6] provided evidence
from Ghana and Tanzania on the cost of large scale treatment in
schools and the potential savings in using the existing school
infrastructure for treatment. For many recipients, access to the
more numerous schools is more convenient than attending more
distant health facilities [19]. However, where school enrolment is
low and particular groups (for example girls or the poorest
children) are under-represented, there is a need for additional
methods of reaching target populations [7]. Studies in Tanzania
[20] and Uganda [21] have examined the effectiveness of
Community Directed Treatment (ComDT) and school based
treatment in terms of coverage for enrolled and non enrolled
children. In Tanzania coverage in both systems was similar, whilst
in Uganda coverage rates under ComDT was higher; the
associated costs are not discussed.
The evidence on the cost effectiveness of three recent large scale
helminth MDA studies in Sub-Saharan Africa is summarised in
Table 7. This presents the characteristics: treatment strategies,
distribution methods, coverage levels, activities costed, study
duration and the number of treatments rounds provided. Each
of these affects the cost and technical effectiveness of the
programme.
Prevalence and mapping data facilitate treatment prioritisation
of endemic areas. This reduces the numbers treated, easing
pressure on constrained budgets, but allows the option, to treat
targeted at risk adults. Niger and Uganda used a targeted
approach. Burkino Faso undertook a blanket approach and
treated all school children in the first treatment.
Burkina Faso has the lowest financial cost per treatment but
excludes start up, mapping and M&E costs included in the studies
(see Table7); it also has the highest coverage. Coverage is a key
factor in determining costs per treatment; in particular capital and
recurrent costs. Children accounted for all treatments in Burkina
Faso and 53% of treatments in the Niger study. Niger’s targeted
strategy reduced the numbers of children requiring treatment.
This eased the budget constraint allowing the targeted treatment
of adults, and increased the scale economies of the programme.
Niger and Uganda provide a measure of the effectiveness of
treatment. Infections averted are used based on anaemia in
Uganda and schistosomiasis in Niger. The use of a technical
measure of effectiveness provides the opportunity to assess, both
ex-ante and ex-post the potential cost effectiveness of alternative
strategies.
The sub-district school based delivery cost per treatment is
similar between Niger and Burkina Faso (a difference of 10%).
Uganda district school based delivery costs (allowing for central
programme costs) are almost 45% greater than Niger’s. The
reason for this is not clear. It may be that central costs are included
in activities other than ‘‘programme costs’’ Sub district community
delivery cost per treatment in Niger are significantly lower than
Burkina Faso due to the high numbers targeted and treated. The
low levels of enrolment, low school numbers targeted and lower
coverage rates all add to the relative cost per person of the Niger
school based system.
The cost per person treated can be reduced either by increasing
national coverage or by an improvement in resource efficiency.
Alternative means of school based implementation are available
and school based treatment can be delivered by teachers, health
workers or CDDs, training may or not be required annually.
However the differences in delivery will impact on treatment
acceptability [19] and coverage, collaboration and motivation as
well as the variable costs.
The distribution of programme costs in Niger, suggest cost
savings would have greatest impact in drugs and training. Drugs
are a major component of the treatment cost and account for
almost half of the economic cost in the current study, between
27%–46% per district of the economic cost in Uganda and 69% of
Table 7. Comparison of MDA costs of three vertical helminth
control programmes in Sub Saharan Africa.
Background Parameters Note B. Faso Uganda Niger
Strategy a A B B
School net enrolment 2005 b 40% n/a 42%
No. districts in costing paper ALL 6 4
Treatments in study
area & period
3,322,564 432,746 818,562
Study period (years) 2 3 2
Activities included in cost c 1 1+ 1,2,3,4,
National coverage d 91% 79% 66%,78%
PPN treated in
communities: schools
1.5:1 0.6:1 5.2:1
PPN targeted in
communities: schools
e 1.64:1 0.85:1 2.7:1
Costs included f 2, 3a 2,3 1,2,3
Discounted analysis
employed
No Yes Yes
Programme costs/treatment
Economic g n/a n/a 0.54 (0.58)
Financial or programme cost g 0.32 n/a 0.44 (0.48)
Drug cost h 0.22 0.22 0.28
Economic cost/treatment by system
School based g n/a 0.54 0.74 (0.76)
Community based g n/a n/a 0.44 (0.46)
Financial cost/treatment by system
School based g 0.31 0.39 0.45 (0.47)
Community based 0.33 n/a 0.39 (0.41)
Sub district programme delivery cost treatment
Cost/person school
based delivery
i (0.08) 0.16 (0.09) 0.11
Cost/person CDD delivery i (0.11) n/a (0.03) 0.05
Notes.
a A. All SAC 1 treatment over 2 years, B All SAC in target areas & key adults C
SAC 2 or more treatments.
b Rates as reported by UN ISCED level. Uganda rates are considered to be more
the SSA average of 68%.
c 1. MDA 2. mapping 3. M&E 4. Prevalence surveys 5. Screening.
d B. Faso coverage over 2 years (2004–2005), Uganda: coverage in pilot phase
(2003), Niger: coverage in pilot phase (4-2004/4-2005) and second phase (4-
2005/4-2006).
e Based on first year results in Niger and Uganda.
f 1. International support costs, 2. Programme expenditure and costs, 3.
Government contribution a) cash & b) recurrent in kind costs (e.g. staff salaries
and vehicle usage).
g see activities included () including international cost.
h Drug usage estimated in Uganda. In Niger usage is based on district registers
and is not stated in B Faso.
i district costs and () sub district costs. Costs exclude drugs, Uganda delivery
cost is reduced by 5% to allow for central overheads.
n/a not available n/r not relevant.
Sources: [4],[5],[16].
doi:10.1371/journal.pntd.0001326.t007
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(undertaken in 2004/06 by SCI) improved the buyer’s market
power, described by Fenwick and Thompson [12]. On average 3.1
praziquantel tablets and 1.4 albendazole tablets were consumed
per treatment in the current study. Using an estimate of actual
against planned praziquantel usage (3.5 tablets/adult and 2.5
tablets/child), gave an average difference of 6% with a range of
24% to 23% across the four districts. The average rate is
considerably more than the wastage rate of 1% assumed in [5].
This range shows a considerable discrepancy between districts and
emphasises the importance of robust drug monitoring and
reporting system.
Targeted treatment of at risk adults in high endemic areas is
used in Niger and Uganda in line with WHO guidelines. As the
cost per infection averted in adults was 3.5 greater than for a child,
it is important to understand the economic value of adult
treatment. One approach is to assess the direct benefits in terms
of impact on adult productivity and the value of this productivity.
USAID Famine Early Warning System Network (FEWS-NET):
Niger Livelihoods Profiles, provide a useful description of
livelihood profiles in these areas. Two studies, with agricultural
production comparable to that in the Niger study, report the
impact of schistosomiasis on agricultural labour productivity
[22,23]. The impact of schistosomiasis treatment on family labour
in paddy rice growing systems in Mali [22] found that health is
improved due to schistosomiasis treatment. As a result the time
available for farm work by family workers increased by 69 days/
ha. Much of this time was invested in the cultivation of additional
non irrigated land, (0.47 ha) (if it is assumed a family has 7-10
members, the average improvement / person would be 10-7
days.). The days of family farm labour lost due to schistosomiasis
and other parasitic and non parasitic infections was assessed in
rain fed farm systems in Benue State, Nigeria [23]. In these
systems 46% of time lost due to illness was related to
schistosomiasis, an average loss of 18.7 working days per adult.
The cost per adult of infection averted in Niger in the first round is
estimated here as $4.3 (Table 6) equivalent to 3 days of labour
(based on the agricultural day rate ($1.4) in 2005, a year of famine)
or 2.3 days (based on rate of $1.9 in a normal year). This indicates
the potential economic net gain from adult treatment. The gain
could be greater depending on adult rates of re-infection and
consequent treatment need.
Conclusion
The cost of treatment per person is driven by the scale of
treatment. The strategy, in Niger, to include targeted adults as well
as school age children has increased the treatment numbers and
reduced the cost per person treated and increased effectiveness. A
conservative estimate of cost effectiveness over 2 years for the
treated population is estimated to be $1.1 per infection averted for
children and $6.5 for adults.
This study used a targeted treatment strategy; 53% of
treatments were to children, but only 16% of the population
treated received school based treatment. Under these conditions
community based treatment was more cost effective than school
based treatment. In Burkina Faso, only school age children were
treated; 40% of these received school based treatment); the school
based system was more cost effective per treatment. However, the
school and community based distribution systems serve overlap-
ping groups in the population; and was designed to facilitate access
to treatment for different groups and support a coverage rate of
75% or more in target populations. Any improvement in either
system must be the result of improved resource use or increased
coverage at the district and programme level if the change is not to
impact on the effectiveness of the other system.
In designing cost effective and sustainable programmes factors
relating to: the treatment strategy, the demographic mix of the
population served, system acceptability to stakeholders and the
coverage rate need to be taken into account along with logistic
issues such as health staff availability. Economic and financial
assessment of alternative implementation plans should be
undertaken for the project or programme design. This would
support decision makers and programme managers, provide
financial evidence in planning discussions and negotiations and
potentially reduce the need for programme changes to improve
cost effectiveness.
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